Testing genes to guide blood-thinning medicine after stroke or mini-stroke
Tests whether a gene test can help doctors choose medicine for stroke or TIA patients.
Plain-language title generated from the registry record
Registry title: Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
Key facts
- Where
- Birmingham, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 89 years old?
Source: NCT06943586, who can take part
Where in United States
- University of Alabama at BirminghamBirmingham, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Alabama at Birmingham
- Trial code
- NCT06943586
- Record updated
- 23 April 2026
- Original description
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.Read full original descriptionShow less
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing in Patients With Minor Stroke or High Risk TIA (CYP2C19 and Stroke)
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.
Inclusion: Patients 18-89 years of age; admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA; eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well).
Exclusion: prescribed anticoagulation prior to stroke; treated with intravenous thrombolysis; treated with mechanical thrombectomy; diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%); missing NIH Stroke Scale score.